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Abstract
Background: Coated polyglactin 910 suture with chlorhexidine (NEOSORB® Plus) has recently been developed to
imbue the parent suture with antibacterial activity against organisms that commonly cause surgical site infections
(SSI). This prospective, single-blinded, randomized trial, was performed to compare the intraoperative handling and
wound healing characteristics of NEOSORB® Plus with those of the traditional polyglactin 910 suture (NEOSORB®) in
urologic surgery patients.
Methods: Patients (aged 19 to 80 years, n = 100) were randomized in a 1:1 ratio for treatment with either NEOSORB®
Plus or NEOSORB®, and stratified into an open surgery or a minimally invasive surgery group. The primary endpoint was
the assessment of overall intraoperative handling of the sutures. Secondary endpoints included specific intraoperative
handling measures and wound healing characteristics. Wound healing was assessed at one and 11 days after surgery.
Cumulative skin infection, seroma, and suture sinus events within 30 days after surgery were also evaluated.
Results: A total of 96 patients were included, with 47 patients in the NEOSORB® Plus group and 49 patients in the
NEOSORB® group. Scores for intraoperative handling were favorable and were not significantly different between the
two suture groups. Wound healing characteristics were also comparable. The incidence of adverse events was 13.6%,
although none were deemed attributable to the suture, and no difference was observed between the two groups.
Conclusions: NEOSORB® Plus is not inferior to traditional sutures in terms of intraoperative handling and wound
healing, potentially making NEOSORB® Plus a beneficial alternative for patients at increased risk of SSI.
Trial registration: ClinicalTrials.gov: NCT02431039. Trial registration date 14 August 2015.
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Background
Surgical site infections (SSI) are the most common
hospital-acquired infections among surgical patients [1].
The occurrence of SSI is generally influenced by the pa-
tient’s characteristics and underlying conditions, as well
as the type of surgery. Furthermore, some reports have
suggested that the suture knot may be a central reposi-
tory for bacteria that contaminate surgical wounds, as it
provides a nidus or scaffold for bacterial colonization
and replication that may lead to SSI [2]. Therefore, pre-
vention of bacterial colonization at the surgical site with
a coated antibacterial suture may help to reduce the in-
cidence of SSI. While there have been many attempts to
reduce SSI risk by coating the suture material with
various antibacterial components, these products have
not demonstrated verifiable performance in clinical
trials, with the exception of a few.
Hence, to more effectively reduce the risk of suture
contamination and SSI, suture materials were developed
that were coated with more powerful antibacterial agents
such as triclosan (polychloro phenoxy phenol), a
broad-spectrum antimicrobial that is active against both
gram-positive and gram-negative bacteria [3, 4]. Since
2002, when antimicrobial PGLA910 (VICRYL® Plus,
Ethicon, NJ, USA) was first approved by the United
States Food and Drug Administration, a variety of
triclosan-coated sutures have been licensed and used
widely, including triclosan-coated poliglecaprone anti-
microbial suture and triclosan-coated polydioxanone
antimicrobial suture [5]. Although considered safe and
effective for over 30 years [2], some studies have re-
ported the development of bacteria-resistant strains to
triclosan [6, 7]. Therefore, there is a growing need for
novel alternative substances such as chlorhexidine
(CHX), which is known to infuse surgical sutures with
powerful antimicrobial activity.
NEOSORB® Plus (Samyang Biopharmaceutical) is manu-
factured using heat-treatment technology and biodegradable
polymers. In contrast to traditional sutures, NEOSORB® Plus
is coated with CHX acetate, which has antibacterial activity
against the most common pathogens that likely cause SSI.
Moreover, NEOSORB® Plus is designed so that CHX is re-
leased as slowly as possible after implantation. The use of
CHX specifically distinguishes it from other triclosan-coated
sutures, such as Vicryl Plus®, and CHX is an antibacterial
agent that is active against both gram-positive and
gram-negative bacterial strains, as well as fungi in a
dose-dependent manner [8]. It is used principally for its
antiseptic and disinfectant action on wounds, in several
products for oral protection, and in many dentistry applica-
tions [9–11]. T. Koburger et al. compared the antimicrobial
efficacy of the antiseptics PVP-iodine, triclosan, CHX, octe-
nidine, and polyhexanide, all of which are currently utilized
for pre-surgical antisepsis and for the antiseptic treatment of
skin, wounds, and mucous membranes based on inter-
nationally accepted standards [12]. The study showed that
CHX and triclosan are effective agents with equally low
maximum values for prolonged contact time. In terms of
immediate effect, CHX is more effective than triclosan.
CHX also demonstrates low mammalian toxicity based on
pharmaceutical testing, and binds strongly to mucosa and
skin [13]. These results suggest that the coated PGLA910
suture with CHX may have extensive utility as an antibacter-
ial suture. We assumed that the CHX-coated PGLA910 su-
ture would be more effective than conventional sutures in
terms of wound healing and SSI prevention in patients
undergoing a variety of surgeries. However, since the
CHX-coated PGLA910 suture is a novel formulation and
has not yet been used on humans, it is important to demon-
strate its safety and feasibility. In this prospective, a
single-blinded randomized controlled trial was undertaken,
whose aim was to demonstrate the safety and efficacy of this
suture and to establish that the effectiveness of the new su-
ture does not fall below a pre-stated non-inferiority margin
(alternative hypothesis). In addition, we sought to prove that
the coated PGLA910 suture with CHX does not negatively
impact wound healing compared to the conventional coated
suture.
Methods
Trial design and participants
We designed a prospective, single-blind, randomized con-
trolled, non-inferiority trial at a single center institution
comparing the intraoperative handling of suture materials
and wound healing outcomes in urologic surgery requir-
ing closure of the fascia and subcutaneous tissue. The trial
was registered on the ClinicalTrial.gov database as
NCT02431039. We strictly followed the 2010 CONSORT
statement to design and report this trial [14, 15]. A total
of 110 patients were screened, and 100 patients (aged 19
to 80 years) were enrolled and randomly assigned to the
NEOSORB® Plus group (n = 50) or a control (NEOSORB®)
group (n = 50) at a 1:1 ratio according to the type of sur-
gery (open surgery or minimally invasive [laparoscopic or
robotic] surgery) as a stratification factor. The flow chart
of patient enrollment, allocation, and follow-up is shown
in Fig. 1. The inclusion criteria were as follows: age 19 to
80 years, clean or clean-contaminated surgery, urologic
surgery requiring closure of the fascia and subcutaneous
tissue, and participants who voluntarily signed our clinical
trial agreement.
The exclusion criteria included the following: contami-
nated surgery; wounds requiring retention suture; sus-
pected malnutrition status; active infection status or
AIDS; incision sites prone to expand, stretch, distend, or
require support; allergy or hypersensitivity to CHX; and
any significant active medical illness which, in the opinion
of the investigator, would preclude protocol treatment.
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Interventions
All wounds in this study consisted of deep incisions that in-
volved deep soft tissues, muscle, and fascia. The test suture
was NEOSORB Plus® and the control suture was the con-
ventional coated PLGA910 suture (NEOSORB®). Surgeries
were performed using the standard urological surgery ap-
proach for either open or minimally invasive surgery. Ac-
cording to the randomization protocol, the patient’s fascia
and subcutaneous tissue repairs were closed with either
CHX-coated or non-CHX coated absorbable sutures. Vari-
ous suture sizes were employed for both the test and con-
trol sutures. Wound closure was achieved using routine
urologic procedure techniques (subcuticular suture). Post-
operative wound dressing was performed once every two
days starting at postoperative day (POD) 1.
Outcomes
Six surgeons (JHP, JKK, JHK, CK, HHK, and CWJ)
assessed the intraoperative suture handling characteristics.
The primary endpoint was the surgeon’s assessment of the
overall intraoperative handling characteristics of each type
of suture. Secondary endpoints included the assessment of
wound healing and of specific intraoperative suture hand-
ling characteristics. The intraoperative suture handling
characteristics evaluated included the following: ease of
passage through the tissue, first throw knot holding, knot
tie-down smoothness, knot security, surgical hand mem-
ory, and degree of fraying (Table 1). The handling charac-
teristics of all test sutures were rated on a five-point scale
as follows: 1 = excellent; 2 = very good; 3 = good; 4 = fair;
and 5 = poor. Wound healing assessments included the
healing progress, skin temperature, and the presence of
infection, edema, erythema, seroma, and suture sinus
(Table 2). Wound healing was evaluated at one (+ 1) day
(POD1) and 11 (±4) days (POD11) following surgery. The
cumulative events of skin infection, seroma, and suture
sinus were again evaluated 30 days postoperatively
(POD30).
Fig. 1 CONSORT participant flow diagram
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Randomization and blinding
A researcher in our department screened and enrolled
the study participants, who were assigned to either the
intervention or the control group by an online
computer-generated randomization sequence. The
randomization process was guaranteed and managed ex-
clusively by Seoul National University Hospital Medical
Research Cooperation Center (MRCC), which had no
role in recruitment. Permuted-block random allocation
with varying block sizes was performed. The participants
were not informed as to whether they were assigned to
the study group or the control group until the end of
the study. The blinding could be broken at the end of
the study if requested by the patients or caregivers, but
the blinding could not be broken during the follow-up
period. The revelation of the random allocation to pa-
tients by the lead investigator was permitted in the event
of an emergency threatening the patient’s safety or
health.
Statistical methods and sample size
Analysis was based on a per-protocol analysis and re-
stricted to the participants who fulfilled the protocol in
terms of eligibility, interventions, and outcome assess-
ment. Evidence of sample size calculation was based on
the following sequence. To show non-inferiority, the
upper limit of the 95% confidence boundary of the dif-
ference between the two groups could not exceed 20%.
Since our study was an exploratory clinical trial and the
primary endpoint was not related to patient survival, we
decided to set a non-inferiority margin of 20% by clinical
judgment. Considering an 80% power and a one-sided
type 1 error of 5%, a total of 100 patients (50 in each
group) were required to allow for a 2% dropout rate. Lo-
gistic regression analysis was used to evaluate intraoper-
ative suture handling techniques. The difference in
wound assessment and adverse events between the two
groups was analyzed using the Fisher exact test (two--
sided). All statistical analysis was conducted using SPSS®
Statistics 21.0. The P value was considered statistically
significant if less than 0.05.
Results
Patient population
A total of 100 patients were enrolled and randomized in
this study. Four patients withdrew from the trial, leaving
47 patients in the NEOSORB® Plus group and 49 pa-
tients in the control (NEOSORB®) group, for a total of
96 treated patients (Additional file 1). Of the four pa-
tients who withdrew, two were removed from the study
Table 1 The handling characteristics of all test sutures were
rated on a five-point scale as follows: 1 = excellent, 2 = very
good, 3 = good, 4 = fair, and 5 = poor
Primary endpoint
Overall handling The composite evaluation of the suture on all
rated characteristics.
Secondary endpoints
Ease of passage The ease with which a suture passes through the
tissue into which it is being implanted.
First-throw knot
holding




The capacity of a suture to allow a throw or knot
to be tied at some distance from its final location
and then slide into place with the next throw.
Knot security The quality of a suture that allows it to be tied
securely with a minimum number of throws
per knot.
Surgical hand The surgeon’s gloved feel or tactile reaction to
handling the suture.
Memory The capacity of a suture to remain relatively free
of kinking, curling, and other contortions that
may interfere with surgical handling and use.
Lack of fraying Capacity of the suture to resist shredding or
unraveling.
Table 2 Wound healing assessments
Parameter Outcome measurement
Healing progress, apposition Complete Incomplete
Infection No Yes
Seroma No Yes
Suture sinus No Yes
Erythema 0 1+ 2+ 3+
None Linear redness Redness < 2 mm Redness > 2 mm
Edema 0 1+ 2+ 3+
None Slight increase in firmness Skin dimples with pressure Tense firmness
Pain 0 1+ 2+ 3+
None With pressure With touching Constant
Skin temperature 0 1+ 2+ 3+
None Slight Definite Hot or radiating
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because their surgery was canceled just prior to
anesthesia. One patient withdrew because of a change in
the operation plan during surgery, and the fourth patient
dropped out because of a research violation. Thus, 96
patients overall provided the basis for examining the
baseline data, safety assessments, the primary endpoint
of overall intraoperative handling, and the secondary
endpoints of specific intraoperative handling measure-
ments. Baseline characteristics were similar between the
two treatment groups (Table 3). Patients were divided
into either an open surgery group (n = 48) or a minim-
ally invasive surgery group (n = 48) depending on the
type of surgery received, as a means of stratification.
Primary endpoint
Regarding the primary endpoint, 97.8% of the responses
rated the handling as “very good” or “excellent” for
NEOSORB® Plus and the difference between groups was
statistically significant (P < 0.001) (Fig. 2). In the open
surgery group, “very good” or “excellent” overall intraop-
erative handling scores were recorded for NEOSORB®
Plus in 100.0% of cases, compared with a mean of 64.0%
of cases for NEOSORB® (P = 0.001). In the minimally in-
vasive surgery group, “very good” or “excellent” scores
were recorded for NEOSORB® Plus in a mean of 95.8%
of cases compared with 75.0% of cases for NEOSORB®
(P = 0.041) (Fig. 3).
Secondary endpoints
The results relative to the secondary endpoints, namely
specific intraoperative handling characteristics, are shown
in Figs. 2 and 3. “Very good” or “excellent” scores were
recorded for NEOSORB® Plus in 98.5% of cases compared
with 69.7% of cases for NEOSORB®. The scores for all
specific intraoperative suture handling measures (ease of
passage, first-throw knot holding, knot tie-down smooth-
ness, knot security, surgical hand memory, and degree of
fraying) in the NEOSORB® Plus group were higher overall
than those of the NEOSORB® group, and the difference
between the groups was statistically significant. In the
minimally invasive surgery group, “very good” or “excel-
lent” scores for specific intraoperative handling character-
istics were recorded for NEOSORB® Plus at a rate of
97.6% compared with 75.6% for NEOSORB® (P = 0.041).
In the open surgery group, “very good” or “excellent”
scores for all specific intraoperative suture handling mea-
sures in the NEOSORB® Plus group (mean 99.4%) were
higher overall than those of the NEOSORB® group (mean
64.0%). The difference between the groups was statistically
significant (P = 0.001) (Fig. 3).
The scores for the wound healing parameters, which
were similar between the two groups, are shown in
Table 4. The majority of wound erythema was mild
and healed quickly. Edema occurred in 51.1% of the
NEOSORB® Plus group versus 59.2% of the NEO-
SORB® group at POD1. However, most of the edema
had disappeared at POD11. Of the patients receiving
perioperative antibiotics, 17.0% were in the NEO-
SORB® Plus group and 18.4% were in the NEOSORB®
group. On POD11, 6.4% of the NEOSORB® Plus
group versus 4.1% of the NEOSORB® group had taken
antibiotics for various reasons, whereas by POD30,
none of the patients were taking antibiotics. The total
number of cases of skin infection, seroma, and suture
sinus within 30 days of after surgery was five in the
NEOSORB® Plus group and two in the NEOSORB®
group. The differences in these events between the
two groups were not statically significant (P > 0.05).
Adverse events
Cumulative adverse events were reported in 8.5% of
patients treated with NEOSORB® Plus and in 6.1% of
patients treated with NEOSORB® (Table 5). Four patients
experienced wound complications and two of these re-
quired wound revision. One patient in the NEOSORB®
group was diagnosed with pre-renal azotemia. Overall,
none of the adverse events was device-related, and there
was no difference between the treatment groups.
Certificate of non-inferiority
The lower value of the two-sided 90% CI of the mean
difference was within the pre-specified non-inferiority
margin, which demonstrated the non-inferiority of the
test compared to the control. Furthermore, the test was
superior to the control, based on our ad-hoc analysis
using a chi-square test (Fig. 4).






Age (years) 59.6 ± 12.16 56.16 ± 14.00 0.21
Gender 0.50
Men 35 (74.5%) 35 (71.4%)
Women 12 (25.5%) 14 (28.6%)
History of other disease
HTN 15 (34.5%) 13 (23.4%) 0.32
DM 6 (16.7%) 10 (20.4%) 0.36




Kidney 26 (55.3%) 26 (53.1%)
Bladder 2 (4.2%) 4 (8.2%)
Prostate 16 (34.0%) 15 (30.6%)
Other 3 (6.4%) 4 (8.2%)
Length of incision (cm) 13.30 ± 4.49 14.75 ± 3.90 0.55
HTN hypertension, DM diabetes mellitus
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Fig. 2 Intraoperative handling. Ninety-six patients (NP = 47, N = 49) completed the study and were included in the final analysis. The primary
endpoint of overall intraoperative handling is shown in the first set of bars. Secondary endpoints for individual aspects of intraoperative handling
comprise the remaining bars. Values for good, fair, and poor handling were small and were combined into one measurement. NP, NEOSORB®
Plus; N, NEOSORB®
Fig. 3 Patients stratified by surgery type. NP, NEOSORB® Plus; N, NEOSORB®
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Discussion
Recently, the increased use of minimally invasive surgery
has resulted in a decrease in the incidence of SSIs. This
may be attributable to the smaller incision size, earlier
mobilization, reduction in postoperative pain, better pre-
servation of immune system function, and decreased use
of central venous catheters of minimally invasive proce-
dures [16]. Nevertheless, SSI still poses a threat to patient
health. SSI occurs in 2 to 3% of procedures performed in
the USA and the majority (60%) of SSIs are confined to
the incision site [17, 18]. In 2014, the Korean Surgical Site
Infection Surveillance (KOSSIS) reported that SSI rates
after colectomy and proctectomy in Korea were as high as
10.15 and 13.54%, respectively [19].
Numerous factors have been linked to elevated risk of
SSI, including patient-related factors such as age, sex,
lifestyle, body mass index, pre-existing infection,
diabetes, comorbidities, and surgical history; and
procedure-related factors such as the type of surgery,
pre-surgical preparation, management of infected or
colonized surgical equipment, and antimicrobial prophy-
laxis [20, 21]. In particular, suture knots may be a major
repository of bacteria that can contaminate wounds, be-
cause they cause scarring that can promote reproduction
and replication of bacteria, ultimately leading to SSI.
The most common putative organisms in SSI include
Staphylococcus aureus (S. aureus), Staphylococcus
epidermidis (S. epidermidis), methicillin-resistant S.
aureus (MRSA), and methicillin-resistant S. epidermi-
dis (MRSE) [20, 22]. Therefore, inhibiting the prolifer-
ation of these organisms at the surgical site may
reduce the incidence of SSI.
The suture knot is considered to be a major site of
colonization of bacteria in a wound. Thus, polyglactin-910
Table 4 Wound healing scores and laboratory finding
POD 1 POD 11
aNP bN p NP N p
(n = 47) (n = 49) (n = 47) (n = 49)
Apposition n(%) 2(4.3%) 3(6.1%) 0.52 39(83.0%) 39(79.6%) 0.35
Edema n(%) 24(51.1%) 29(59.2%) 0.43 2(4.3%) 1(2.0%) 0.49
Erythema, any n(%) 42(89.3%) 38(77.6%) 0.31 7(14.8%) 4(8.2%) 0.52
Pain, any n(%) 43(91.4%) 41(83.6%) 0.50 5(10.6%) 4(8.2%) 0.55
Antibiotics n(%) 8(17.0%) 9(18.4%) 0.59 3(6.4%) 2(4.1%) 0.52
Skin temp n(%) 24(51.1%) 21(42.9%) 0.47 2(4.3%) 1(2.0%) 0.49
Infection n(%) 0(0%) 0(0%) – 1(2.1%) 0(0%) 0.35
Seroma n(%) 0(0%) 0(0%) – 2(4.3%) 1(2.0%) 0.49
Suture sinus n(%) 2(4.3%) 0(0%) 0.24 2(4.3%) 1(2.0%) 0.49
Laboratory data
WBC (103/μl) 11.21 ± 0.42 10.83 ± 2.74 0.51 7.33 ± 1.92 7.31 ± 1.69 0.95
ANC(103/μl) 8.40 ± 2.78 8.05 ± 2.78 0.55 4.46 ± 1.65 4.47 ± 1.49 0.97
AST(IU/l) 28.02 ± 18.57 26.72 ± 16.64 0.71 22.35 ± 10.62 20.50 ± 9.58 0.37
ALT(IU/l) 27.59 ± 27.40 25.68 ± 21.86 0.70 28.63 ± 18.90 26.60 ± 16.09 0.57
CRP(mg/dl) 3.59 ± 4.74 4.10 ± 5.76 0.64 0.65 ± 1.12 0.84 ± 1.38 0.47
CRP C-reactive protein, WBC white blood cell count, ANC absolute neutrophil count, AST aspartate aminotransferase; Alanine transaminase
aNP, NEOSORB® Plus; bN, NEOSORB®
Table 5 Cumulative adverse events
Adverse events, n, (%)
Any Serious Requiring surgery Device-related
Open surgery aNP (n = 23) 2 (8.7) 0 0 0
bN (n = 25) 3 (12.0) 2 (8.0) 1 (4.0) 0
Minimally invasive surgery NP (n = 24) 2 (8.3) 1 (4.2) 1 (4.2) 0
N (n = 24) 0 0 0 0
All patients N (n = 96) 7 (7.3) 3 (3.1) 2 (2.1) 0
aNP, NEOSORB® Plus; bN, NEOSORB®
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and polydioxanone sutures coated with triclosan have
been developed to confer antimicrobial activity against the
most common pathogens in suture materials [2, 23].
Several clinical studies of various cohorts of surgical
patients have examined whether triclosan-coated
sutures effectively decrease the rate of surgical site in-
fections [24–26]. Two recent meta-analyses demon-
strated that they do in fact exert a positive effect on SSI
reduction [27, 28]. However, bacterial resistance to
triclosan has increased and warnings of potential
pathogen selections are being emphasized [6, 7].
Segers et al. showed that CHX is effective against a
broad spectrum of relevant pathogens including clinic-
ally problematic bacteria like S. aureus [29], and CHX
has already been approved for use in a variety of medical
applications such as medical device coatings, a skin anti-
septic, and an oral antiseptic [30–34]. Andreas et al.
evaluated novel CHX coatings for antimicrobial surgical
sutures in vitro [35] and demonstrated their high anti-
microbial efficacy against S. aureus. In particular,
CHX-coated sutures with an 11 μg/Cm concentration
were shown to have acceptable cytotoxicity according to
ISO 10993–5 standards and simultaneously high anti-
microbial protection over several days. Hence, such
coated sutures can be a viable alternative to prophylactic
sutures in cases of increased risk of SSI.
To our knowledge, this is the first study to evaluate
the safety and efficacy of CHX-coated sutures compared
with a conventional suture in humans. The incidence of
adverse events between the groups was not different,
and no adverse event was deemed related to the suture
material in this trial. The findings demonstrated that
NEOSORB® Plus was not inferior to a conventional su-
ture in terms of overall intraoperative handling. In
addition, there was no significant difference in wound
healing outcomes between the two types of sutures.
With regard to the wound healing parameter assess-
ments, a high incidence of erythema and wound site
pain at POD1 was seen in this study in both groups,
though the erythema was generally mild and the lesions
healed within one or two days. Likewise, most patients
who complained of surgical wound pain showed im-
provement in only a few days. We consider the high in-
cidence of surgical wound pain and erythema to be
attributable to our rigorous assessment.
In the present study, NEOSORB® Plus was not inferior
to NEOSORB® in overall handling compared to open
surgery and laparoscopic surgery wounds. In particular,
there were statistically significant differences between
the NEOSORB® and the NEOSORB® Plus group in some
subjects. Since NEOSORB® Plus is a newly developed
product, it is likely that the needle of the instrument and
the coating of the thread have been upgraded since the
design of the traditional suture.
There are some limitations to the present study. First,
this was a single-blinded study, where the patients did
not know the group to which they were assigned. How-
ever, potential bias may have occurred because surgeons
who assessed the intraoperative suture handling charac-
teristics were not blinded. To overcome this limitation,
six surgeons, with the exception of the surgeon most
closely responsible for the analysis and design of the
Fig. 4 This non-inferiority threshold is the maximum allowable excess of outcome events arising from the Neosorb® Plus compared to
the Neosorb®
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study (BST), assessed the intraoperative suture handling
characteristics. Second, all of the surgical interventions
in this trial were clean or clean-contaminated elective
surgeries, as are the majority of urologic surgeries. In
clean or clean-contaminated surgery, SSI risk is generally
minimal and originates only from contaminants in the
operation room environment or from the surgical team,
or most commonly from skin colonists. Therefore, we
concluded that NEOSORB® Plus showed no significant
differences compared to traditional sutures in terms of
the wound healing assessment in this study. In addition,
the aim of this trial was to provide evidence for the
safety and efficacy of NEOSORB® Plus, and to estab-
lish that the effectiveness of the new suture does not
fall below a pre-stated non-inferiority margin. To
demonstrate that NEOSORB® Plus is actually superior
to the traditional suture in terms of SSI, a larger sam-
ple of participants is needed. However, since CHX did
not show a negative influence on wound healing and
there were no issues with the physical properties of
NEOSORB® Plus in this trial, we were able to at least
recognize the overall safety and feasibility of NEO-
SORB® Plus. In addition, further studies are expected
to validate the antibacterial potential of NEOSORB®
Plus in the context of other types of surgery and con-
taminated surgeries. Third, at the beginning of this
study, a 2% dropout rate was expected, but by the
end of the study a 4% dropout occurred. This may
constitute an additional limitation, in that the power
can be lowered. However, the sample size was suffi-
cient to demonstrate the non-inferiority, as shown in
Fig. 4, likely because the power was stronger than ex-
pected when we established our hypothesis.
As mentioned above, the original coated surgical suture,
the coated PGLA910 suture with triclosan (VICRYL® Plus,
Ethicon, NJ) is widely used in a variety of surgery depart-
ments. Numerous studies in vivo and in vitro have shown
that triclosan-coated sutures are associated with a
significantly lower risk of SSI than uncoated sutures [5].
In order to demonstrate the efficacy of NEOSORB® Plus
as an alternative choice for SSI prevention, future trials
with larger sample sizes are needed to accurately compare
the efficacy and safety of CHX-coated sutures with that of
triclosan-coated sutures.
Conclusion
Our results indicate that the NEOSORB® Plus antibac-
terial suture (coated PGLA910 suture with CHX) is
not inferior to the traditional suture in terms of intra-
operative handling and wound healing. Further large,
prospective clinical trials are warranted to validate
our findings and to evaluate the potential of reduced
SSI in different surgical contexts.
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